Clinical Trials Browser

Phase 3 × Anatomic Stage I Breast Cancer AJCC v8 × Trastuzumab × Clear all

NCT06876714 2026-06-02

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Phase 3 Recruiting

Anatomic Stage I Breast Cancer AJCC v8